Kylie Bromley, managing director of Biogen UK, said the rise in the amount of money Nice is prepared to pay for drugs is long ...

Limited treatment options and access to care often challenge patients with Friedreich’s ataxia. So, on Sept. 17, the ...

"I don't know if you've heard about it," says the long-adored scientist and climate activist—plus, the one rising condition that tells him "there's something going on." ...

Researchers at Ruhr University Bochum, Germany, identified a receptor that plays a crucial role in stress-induced motor ...

Your body can't produce vitamin B12 on its own, so getting it from your diet is important. If you're just starting to study it, we'll help you understand it further.

Could an anomaly in the developing brain explain motor difficulties occurring decades later in people with rare movement ...

Daniel Fraser, 36, was diagnosed with Friedreich’s Ataxia, a progressive disease that causes mobility, speech issues and ...

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...

Lexeo Therapeutics (LXEO) stock rises as the FDA supports a potential accelerated approval pathway for LX2006, its treatment for Friedreich ataxia. Read more here.

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Larimar Therapeutics, Inc. (NASDAQ: LRMR) resulting from ...